Research ArticleBasic Science Investigations
Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib
Alexander Traxl, Thomas Wanek, Severin Mairinger, Johann Stanek, Thomas Filip, Michael Sauberer, Markus Müller, Claudia Kuntner and Oliver Langer
Journal of Nuclear Medicine December 2015, 56 (12) 1930-1936; DOI: https://doi.org/10.2967/jnumed.115.161273
Alexander Traxl
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
Thomas Wanek
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
Severin Mairinger
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
Johann Stanek
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Thomas Filip
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
Michael Sauberer
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
Markus Müller
2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Claudia Kuntner
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
Oliver Langer
1Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; and
2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 12
December 1, 2015
Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib
Alexander Traxl, Thomas Wanek, Severin Mairinger, Johann Stanek, Thomas Filip, Michael Sauberer, Markus Müller, Claudia Kuntner, Oliver Langer
Journal of Nuclear Medicine Dec 2015, 56 (12) 1930-1936; DOI: 10.2967/jnumed.115.161273
Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib
Alexander Traxl, Thomas Wanek, Severin Mairinger, Johann Stanek, Thomas Filip, Michael Sauberer, Markus Müller, Claudia Kuntner, Oliver Langer
Journal of Nuclear Medicine Dec 2015, 56 (12) 1930-1936; DOI: 10.2967/jnumed.115.161273
Jump to section
Related Articles
Cited By...
- ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery
- A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier
- EGFR is required for FOS-dependent bone tumor development via RSK2/CREB signaling
- Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET
- Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [11C]erlotinib and Positron Emission Tomography
- Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates